Christine Baeder, chief operating officer for generics and biosimilars at Teva USA and newly named chair of the Association for Accessible Medicines, tells this week’s Video Forum about the threats facing the generic pharmaceutical industry and what should be done to counter them. She also discusses the relatively slow pace of adoption of biosimilars in the U.S., the impact of innovative payment models on the marketplace, and the value that generics represent.
Video Forum: Christine Baeder, Teva USA

Latest


Albertsons reports solid Q1 as digital and pharmacy sales drive growth
“We delivered solid operating and financial performance while investing in our core operations and enhancing our customer value proposition.”

FMI urges FDA to revise food traceability and labeling rules to reduce burdens, avoid cost hikes
“FMI strongly supports the work of HHS and FDA to identify and eliminate outdated or unnecessary regulations.”

Walmart wooing back-to-school shoppers by doubling down on value and convenience
“We understand how important it is for families and teachers to save time and money when preparing for the school year.”